Cell and gene therapies are transforming modern medicine, and CAR T cells are among the most promising immunotherapies. Building on an ERC-funded discovery platform, Christoph Bock’s team will further develop CRISPR-enhanced CAR T cells and prepare them for clinical testing in collaboration with the Medical University of Vienna.